94 results on '"Kumada, Hiromitsu"'
Search Results
2. A Post-marketing surveillance of ombitasvir/paritaprevir/ritonavir for patients with hepatitis C virus genotype 1b infection: A follow-up study of phase 2 and 3 clinical trials
3. Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment
4. Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus
5. Comparison between Lumipulse Presto HBsAg-HQ and iTACT-HBsAgin Chronic Hepatitis B with Seroclearance of HBsAg by Architect HBsAg QT
6. Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy
7. Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment
8. Relationships between HCV genotype and serological group in patients, except for genotype 1 or 2
9. Treatment efficacy of all-oral combinations of direct-acting antivirals in chronic hepatitis C patients with NS5A-P32 deletion
10. Safety and efficacy of ombitasvir/paritaprevir/ritonavir in genotype 1b-infected elderly Japanese patients in the GIFT-I study
11. Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-
12. Evaluation of the clinical utility of Cobas TaqMan HCV v2.0
13. Clinical utility of the HCV drug resistance assay using the direct sequencing method and the cycleave PCR method in the dual therapy with daclatasvir and asunaprevir
14. A new risk estimation scale of HCC development, named JAB-HCC score (Japanese risk estimations of HBV-related HCC), shows a good discrimination capability
15. Correlation between efficacy of daclatasvir/asunaprevir combination therapy and HCV NS3/NS5A resistance-associated variants detected by the PCR-Invader assay
16. JSH guidelines for the management of hepatitis C virus infection (ver 3; abstract)
17. Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)
18. Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay
19. Guidelines for the management of hepatitis B virus infection
20. Combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for hepatocellular carcinoma
21. Study of peginterferon alfa-2b plus ribavirin combination therapy in type C compensated liver cirrhosis
22. Telaprevir in combination with peginterferon alfa-2b and ribavirin therapy for genotype 1 Japanese chronic HCV patients: Impact on adherence and antiviral effects
23. Efficacy and safety of treatment with peginterferon alfa-2a for chronic hepatitis B patients
24. A pilot study of triple therapy with telaprevir 1500 mg, peginterferon and ribavirin for elderly HCV patients
25. Treatment Guidelines of Hepatitis C
26. Round-table discussion: Various problems over hepatitis B treatment
27. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B
28. Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders
29. The evaluation of the sensitivity between serum and plasma specimen for COBAS TaqMan HBV v2.0
30. Relationship between SNPs in the IL28B region and amino acid substitutions in HCV core region in Japanese patients with chronic hepatitis C
31. Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis
32. Increase of rtA181T mutant strains during entecavir therapy for a patient with chronic hepatitis B virus infection
33. Round-table discussion: Current treatment of hepatitis C
34. The efficacy of virological response in treatment-naïve patients with chronic hepatitis C treated by NS3-4A protease inhibitor (telaprevir) , pegylated interferon and ribavirin for 12 weeks
35. JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B
36. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis
37. Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
38. JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C
39. Influence of HMG-CoA reductase inhibitor to virological response of peginterferon/ribavirin combination therapy in chronic hepatitis C
40. Re-evaluation of chronic hepatitis C patients who showed viral relapse after interferon plus ribavirin therapy by COBAS AmpliPrep/ COBAS Taq Man HCV Test
41. Round-table discussion: Current treatment of hepatitis C based on experimental and clinical evidence
42. Low density lipoprotein cholesterol levels and amino acid substitutions in HCV core region are important pretreatment predictors of response to treatment with peginterferon plus ribavirin in Japanese patients with chronic hepatitis C
43. An Adult Case of Fulminant Wilson's Disease
44. Forefront of radiofrequency ablation therapy for liver cancer: a foreword
45. Changes of laparoscopic histological findings in three cases of chronic hepatitis-B treated with Lamivudine.
46. The efficacy of prolonged natural interferon-.ALPHA. therapy for chronic hepatitis C.
47. Long-term observation of four patients with early stage of primary biliary cirrhosis(PBC).
48. A pilot study of combination therapy with interferon-.ALPHA. and interferon-.BETA. for the patients with chronic hepatitis C resistant to interferon therapy.
49. Diagnosis of small hepatic nodular lesion determined by magnetic resonance imaging(MRI) under breath holding.
50. A prospective randamized admininstration of Stronger-Neo-Minophagen C as an adjuvant therapy for chronic hepatitis type C treated with interferon.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.